30+ years of experience in biopharmaceuticals and venture capital.
Executive positions at Knoll and Novartis, General Manager Actelion Pharmaceuticals.
Expertise in drug development, commercial operations, and B&D.
Contributed to the success of the startup Actelion, acquired for $30 bi.
VC (FinHealth), investing in and supporting life science portfolio companies.
PhD in Biology and a BA in Chemistry from the University of Mainz, Germany.

Successful serial entrepreneur in Life Sciences, founded 4 companies.
Groundbreaking, highly cited researcher in the field of Panx1 and blocking Panx1 as a therapeutic approach, +10 years.
Effectively translating science into products and raising funds from private and public sources.
Ph.D. in Neuroscience from the University of Santiago, Chile.
Received the National Prize of Innovation in Chile in 2015.

30+ years of experience in global pharmaceutical companies in general drug development, drug discovery, screening, and profiling lead candidates.
Key role in drug development and registration at Aventis, Novartis, AstraZeneca, Lundbeck, and Janssen.
14 FDA-approved drugs in the market.
Notable successes include Leflunomide, Glivec, Myfortic, Zelmac, Everolimus, and Aliskiren.
Ph.D. in Organic Chemistry from the University of Marburg, Germany.